What did @makayla.woods3 actually say?
Here is the awkward truth: the transcript for this video is not a health claim at all. The words captured are song lyrics, something along the lines of "it's been a long time" and "you better gravitate." The actual health claims in this fact-check come entirely from the written caption, not from anything spoken on camera.
The caption claims that injecting peptides in the inner thigh "may help decrease side effects and improve absorption," that peptides help control appetite, support blood sugar balance, and work best with high protein intake. These are specific clinical-adjacent claims. They deserve scrutiny whether they came from a voiceover or a text overlay, because viewers are reading them and potentially acting on them.
Worth noting: the hashtag "xmd" and the handle "nursemakayla" suggest a clinical persona is being projected here. That raises the bar for accuracy.
Does the science back this up?
The absorption and injection-site claim is the weakest of the bunch, and the blood sugar and appetite claims depend entirely on which peptide is actually being discussed. Without naming a specific compound, these statements float in a vague space that sounds credible but proves very little.
On injection sites: subcutaneous injections are typically administered in the abdomen, upper arm, or thigh. The inner thigh as a preferred site for reducing side effects is not well-supported in peer-reviewed literature for most peptide categories. A 2020 review by Rønholt and Klitgaard in Drug Delivery found that subcutaneous tissue depth and local blood flow affect absorption rates, but no site was universally superior across compound types. The "inner thigh reduces side effects" framing appears to be anecdotal at best.
For GLP-1 receptor agonist peptides, appetite suppression and blood sugar modulation are well-documented. Nauck and Meier (2018, Diabetologia) confirmed GLP-1 analogs meaningfully reduce appetite and improve glycemic control. But calling this a general "peptide fact" without specifying the compound is like saying "pills lower blood pressure" without naming a drug class.
What did they get wrong (or right)?
Let us give credit where it is due. The protein recommendation is directionally correct. Research consistently shows that adequate dietary protein preserves lean mass during caloric restriction, which is relevant if someone is using appetite-suppressing peptides. Morton et al. (2018, British Journal of Sports Medicine) found that higher protein intake during energy restriction protects muscle mass. That part checks out.
What is problematic is the specificity theater. Claiming that the inner thigh injection site "may improve absorption" sounds clinical, but there is no cited evidence, no named peptide, and no mechanism explained. Readers will likely assume this applies to whatever peptide they are using, which could include compounds with entirely different pharmacokinetics. Ipamorelin, BPC-157, and semaglutide do not behave the same way subcutaneously.
The blood sugar and appetite claims are accurate for a narrow subset of peptides, misleading as a general statement. Presenting them as universal "peptide facts" without differentiation is the kind of oversimplification that gets people in trouble.
What should you actually know?
If you are considering peptide therapy, the injection site conversation is not as simple as "inner thigh is better." Subcutaneous absorption depends on local adipose tissue thickness, blood flow, and the specific compound's molecular weight and formulation. A provider should guide injection site selection based on your individual anatomy and the specific peptide prescribed.
Peptides marketed for appetite control and blood sugar support vary enormously in their evidence base. GLP-1 analogs have robust clinical trial data. Many other peptides being sold in this space, including several listed in the FormBlends category context like semax, selank, and MK-677, have limited or primarily preclinical human data. MK-677, for instance, is not a peptide but a growth hormone secretagogue, and its long-term safety profile in healthy adults is not well established (Nass et al., 2008, Annals of Internal Medicine).
Protein intake genuinely matters in the context of peptide-supported body composition work. That is not controversial. But no single TikTok caption replaces a clinical consultation for compounded injectables.